22nd October|News

OptiBiotix leads sector with surging half year interim sales figures

Leading life sciences company OptiBiotix Health Plc (‘OptiBiotix’), which specialises in developing functional ingredients that modulate the microbiome to improve health and wellbeing, has announced major sales growth for its award-winning LPLDL® and SlimBiome® ingredients as part of its half-year interims.

The company’s rapid growth follows its success seen in 2020, where sales increased by 107% for its proprietary probiotic strain, LPLDL®. The ingredient, which aids cardiovascular health, recorded a further 57.5% growth in sales for the six months ending 30 June 2021.

OptiBiotix saw sales for SlimBiome®, a scientifically supported weight management ingredient featuring a blend of dietary fibres and trace minerals, grow by 151% in 2020, followed by a 35.6% growth in the first six months of this year. The growth is contrary to market figures which show that sales of weight management products declined during the Covid-19 pandemic. Data from SPINS (Chicago) on the 52 weeks ending 29 November 2020, for instance, showed an 11% contraction in sales of weight-management supplement ingredients in the US mainstream market1.

Stephen O’Hara, CEO of OptiBiotix, said the sales performance of SlimBiome® and LPLDL® demonstrates the real value that consumers place on products which are evidenced and supported by science.

“Despite several industry challenges over the last year, including the significant impact the Covid-19 pandemic caused on global supply chains, OptiBiotix has seen impressive growth,” he commented. “With interest growing year-on-year in gut health, heart health and the microbiome, we are uniquely placed to make a strong and positive difference to consumer wellbeing with our products, which are backed by clinical studies and key opinion leaders.”

According to the latest report from Euromonitor, consumers are drawn to products that are supported by science and are no longer convinced that taking shortcuts to weight loss is the most effective treatment2. In addition, the latest consumer trends point to clean-label ingredients, with many seeking alternative supplements in heart health that offer more control over their wellbeing3.

This interest, which has been partly fueled by the pandemic and its suggested links to lifestyle diseases, has led to increased market growth for dietary supplements in emerging countries such as India, Brazil, Mexico, Malaysia and Indonesia3 – all key areas of expansion for OptiBiotix.

As such, the global weight management market is now set for an 8% CAGR between 2021 to 20264, according to new insight from Research and Markets, after only moderate growth between 2015 to 2020. While the heart health market is reported to grow at 4.5% CAGR by 20303 – a significant leap compared to just a few years ago as awareness increases among consumers around preventative healthcare.

“As part of our growth strategy, our reach now spans 160 countries within three years of product launches,” continued O’Hara. “In the last six months, we have signed new contracts with Compson Biotechnology in Taiwan, Inscobee Inc. in South Korea and Bioscience Marketing in Malaysia for LPLDL® and our finished product, CholBiome®.

“These deals add to the growing number of partners we have already established for LPLDL® and CholBiome®, including AlfaSigma Pharmaceuticals in Italy and Actial Farmaceutica for the APAC region. In addition, SlimBiome® has also seen similar territorial and product line expansion with partners in Australia through OptiPharm, in the US with Agropur and in the UK through Holland & Barrett.

“With several clinical and scientific studies, a large IP portfolio, and a growing brand presence, we are attracting the interest of major industry players. As such, we are focused on working with partners in areas of strategic interest, such as the US, India and China, and can look forward with confidence for the remainder of this year and as we move into 2022.”

Not only has OptiBiotix seen major sales success this year, but the company has also won and been shortlisted for many awards for both SlimBiome® and LPLDL®. Notable mentions for this year include the Food & Drink Federation Awards, NutraIngredients Asia Awards and the Nutrition Industry Executive Awards.

“To be recognised in several prestigious awards in the health and nutrition sector is already a great honour, but to do so in several regions is extraordinary. With our strong team, science-backed ethos and a rapidly growing portfolio of products, the company is poised for an exciting year ahead in healthcare,” concluded O’Hara.

For more information on OptiBiotix and its activities, please visit optibiotix.com

References
1. SPINS Conventional Channel data (Powered by IRI). “Dietary Supplements (Vitamins & Supplements and Herbs & Homeopathics).” Time period: 52 weeks ending November 29, 2020. Channel: U.S. conventional multioutlet comprising grocery, drug, Walmart, mass dollar, military, and club stores. Excludes private-label brands.

2. Euromonitor International, Weight Management and Wellbeing in the United Kingdom, October 2020.

3. Persistence Market Research, Heart Health Supplements Market, September 2020.

4. Research and Markets, Weight Management Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, June 2021.